Actively Recruiting
Immune Profiling for Cancer Immunotherapy Response
Led by Dartmouth-Hitchcock Medical Center · Updated on 2025-12-16
1500
Participants Needed
1
Research Sites
326 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.
CONDITIONS
Official Title
Immune Profiling for Cancer Immunotherapy Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Cancer patients receiving or will receive immunotherapy under FDA-approved indication (e.g., checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy)
- Participants are eligible regardless of the type of prior therapy, including prior immunotherapy treatments
You will not qualify if you...
- Pregnant women, fetuses, or neonates
- Prisoners
- Individuals with impaired decision-making capacity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Actively Recruiting
Research Team
B
Brock C Christensen, PhD
CONTACT
H
Hannah G Stolrow, BA
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here